Drug Profile
Trastuzumab biosimilar - DM Bio
Alternative Names: DA-3111; DMB 3111Latest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator Dong-A Socio Holdings; Meiji Seika Pharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Gastric cancer; HER2 positive breast cancer
Most Recent Events
- 20 Apr 2022 Trastuzumab biosimilar has completed phase I development, for the treatment of HER2-positive-breast-cancer and Gastric cancers in Japan and South Korea (Meiji pipeline, April 2022)
- 20 Apr 2022 Meiji Seika Pharma and Dong-A complete phase I trial in gastric cancer in South Korea (Meiji pipeline, April 2022)
- 20 Apr 2022 Meiji Seika Pharma and Dong-A complete phase I trial in HER2-positive-breast-cancer in South Korea (Meiji pipeline, April 2022)